The presence of antibodies against the  AD 2 epitope of cytomegalovirus glycoprotein B is associated with acute rejection after renal transplantation | Zendy

Ishibashi Kei | Zendy; Tokumoto Tadahiko | Zendy; Shirakawa Hiroki | Zendy; Oguro Toshiki | Zendy; Yanagida Tomohiko | Zendy; Takahashi Norio | Zendy; Nomiya Masanori | Zendy; Haga Nobuhiro | Zendy; Aikawa Ken | Zendy; Tanabe Kazunari | Zendy; Inoue Naoki | Zendy; Kojima Yoshiyuki | Zendy; Suzutani Tatsuo | Zendy

Premium

The presence of antibodies against the AD 2 epitope of cytomegalovirus glycoprotein B is associated with acute rejection after renal transplantation

Author(s) -

Ishibashi Kei,

Tokumoto Tadahiko,

Shirakawa Hiroki,

Oguro Toshiki,

Yanagida Tomohiko,

Takahashi Norio,

Nomiya Masanori,

Haga Nobuhiro,

Aikawa Ken,

Tanabe Kazunari,

Inoue Naoki,

Kojima Yoshiyuki,

Suzutani Tatsuo

Publication year - 2014

Publication title -

microbiology and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.664

H-Index - 70

eISSN - 1348-0421

pISSN - 0385-5600

DOI - 10.1111/1348-0421.12112

Subject(s) - cytomegalovirus , antibody , transplantation , immunology , epitope , betaherpesvirinae , glycoprotein , kidney transplantation , virology , human cytomegalovirus , medicine , biology , herpesviridae , virus , viral disease , microbiology and biotechnology

The aim of this study was to evaluate the association between antibodies against cytomegalovirus (CMV) glycoprotein B (gB) and acute rejection after transplantation. Seventy‐seven consecutive renal transplant recipients in a D + /R+ setting were studied. Biopsy‐proven rejection occurred in 35% of the recipients. Among these recipients, 85% had antibodies against CMV gB. The rate of acute rejection was significantly higher in recipients with antibodies against gB than in those without them. Antibodies against gB can be a useful predictor of acute rejection in renal transplant recipients in a D + /R+ setting.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research